UBS O'Connor’s Amicus Therapeutics FOLD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
$14.2M Buy
+1,000,000
New +$9.82M 0.38% 26
2016
Q3
– Sell
-59,387
Closed -$324K – 445
2016
Q2
$324K Buy
+59,387
New +$415K 0.01% 357
2015
Q4
– Sell
-80,000
Closed -$1.12M – 474
2015
Q3
$1.12M Sell
80,000
-420,000
-84% -$6.59M 0.01% 424
2015
Q2
$7.08M Buy
500,000
+250,000
+100% +$3.01M 0.06% 294
2015
Q1
$2.72M Buy
250,000
+93,116
+59% +$821K 0.03% 356
2014
Q4
$1.3M Buy
+156,884
New +$1.08M 0.02% 325

Other funds holding FOLD

UBS O'Connor's FOLD Position: Q4 2025 in Review

UBS O'Connor opened a new position in Amicus Therapeutics (FOLD) in Q4 2025: 1,000,000 shares worth $14.2M. The stake represents 0.38% of the portfolio and ranks #26 among its holdings. This is a return to the name: UBS O'Connor previously reported a position in FOLD as recently as Q2 2016.

UBS O'Connor first reported a position in FOLD in Q4 2014 and has held it in 6 quarters since. 332 funds tracked by Wall St. Rank hold FOLD as of Q4 2025.

  • UBS O'Connor held 1,000,000 shares of Amicus Therapeutics worth $14.2M as of Q4 2025.
  • Amicus Therapeutics was a new UBS O'Connor position in Q4 2025.
  • Amicus Therapeutics made up 0.38% of UBS O'Connor's portfolio in Q4 2025, its #26 holding.
  • UBS O'Connor first reported a position in Amicus Therapeutics in Q4 2014 and has held it in 6 quarters since.
  • 332 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q4 2025.

Based on UBS O'Connor's 13F filing for Q4 2025, filed 13 Feb 2026.